Key result
Ramipril daily reduced the risk of major vascular events compared to placebo in elderly patients with vascular disease.
Why the study?
Does ramipril 10 mg daily reduce major vascular events in elderly patients (≥70 years) with vascular disease or diabetes and without heart failure?
RCT (n=2,755)
Does ramipril 10 mg daily reduce major vascular events in elderly patients (≥70 years) with vascular disease or diabetes and without heart failure?
Ramipril 10 mg daily significantly reduces the risk of major vascular events, cardiovascular death, myocardial infarction, and stroke in elderly patients (≥70 years) with high-risk vascular disease or diabetes without heart failure.
Answers are grounded in this paper and cite their sources.
Supports ramipril 10 mg daily in high-risk elderly patients without heart failure; extends prior trial evidence to those ≥70 years.
AIMS: Cardiovascular (CV) disease is the leading cause of death in the elderly. The use of ACE-inhibitors in elderly patients with chronic stable vascular disease has not been previously reported. METHODS AND RESULTS: The HOPE trial evaluated the effects of ramipril and vitamin E in high-risk vascular disease patients. We report the effects of ramipril in the elderly HOPE study patients, defined as those > or =70 years of age. A total of 2755 elderly patients with vascular disease or diabetes and at least one additional CV risk factor and without heart failure or low ejection fraction were randomized to ramipril 10 mg daily or placebo. Those assigned to ramipril had fewer major vascular events compared to those assigned to placebo [18.6 vs. 24.0%, hazard ratio (HR) = 0.75, P = 0.0006], CV deaths (9.3 vs. 13.0%, HR = 0.71, P = 0.003), myocardial infarctions (12.0 vs. 15.6%, HR = 0.75, P = 0.006), and strokes (5.4 vs. 7.7%, HR = 0.69, P = 0.013). Treatment was safe and generally well tolerated. CONCLUSION: Ramipril reduces the risk of major vascular events in elderly patients with vascular disease and is safe and well tolerated by most.
No takes yet. Share an insight, caveat, or question.
Gianni et al. (2007) conducted an RCT in vascular disease or diabetes with additional CV risk factor (n=2,755). ramipril vs. placebo was evaluated on major vascular events (HR 0.75, p=0.0006). Ramipril daily reduced the risk of major vascular events compared to placebo in elderly patients with vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: